Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call Transcript November 6, 2024 Teva ...
As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...
Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...
QRG Capital Management Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 1.6% during the third quarter, according to the company in its most recent Form ...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...
On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback